Comparison between Iodixanol and Iohexol for Cervical Myelography in Cat
Authors
Abstract:
Objective- To evaluate and compare the radiographic efficacy and safety of a non-ionic dimeric and isotonic iodinated contrast medium, iodixanol (320 mgI/ml) and a non-ionic monomer and hypertonic contrast medium, iohexol (300 mgI/ml) in feline cervical myelography. Design- Experimental study Animals- Five adult healthy cats. Procedures- Iodixanol and iohexol were injected into the cerebellomedullary cistern. Radiographs were obtained immediately, 10, 20, 40 and 60 minutes after injection. The myelograms were scored and analyzed for statistical significance. Results- Diagnostically adequate radiographic examinations were obtained with both agents. Adequate opacity in thoracic and lumbar vertebrae was obtained after 10 and 20 minutes post injection for both contrast agents. After 40 minutes contrast agents were had reached the end of lumbar vertebrae column. No significant differences in scoring for image quality were observed between two contrast mediums (p>0.05). Iodixanol and iohexol radiopacified cervical region immediately after injection. Adequate opacity in thoracic and lumbar vertebrae was obtained after 10 and 20 minutes post injection for both contrast agents. Evaluation of each of the radiographs showed good to excellent opacification. No clinical and neurological abnormalities were found related to the myelographic procedure during one week after injection. Vital signs, CBC and some serum biochemical examinations remain in normal ranges. Conclusion and Clinical Relevance- Iodixanol and iohexol proved to be safe and effective contrast materials for myelographic studies in cats. More mean score of iodixanol suggests that, it is preferable to perform myelography with iodixanol.
similar resources
Comparison of iodixanol and iohexol in renal impairment.
Iodixanol (Visipaque, Nycomed, Oslo, Norway) is an iodinated contrast medium in the form of a non-ionic dimer which is iso-osmolar with plasma at all iodine concentrations. There is little evidence regarding its renal tolerance in renal impairment. We therefore undertook a prospective randomized comparison of iodixanol and the non-ionic monomer iohexol (Omnipaque, Nycomed, Oslo, Norway). The se...
full textIohexol versus metrizamide for cervical myelography: double-blind trial.
Cervical myelography was performed by lateral C1-C2 puncture in 60 patients. Thirty patients received iohexol (an investigational aqueous contrast agent) and 30 received metrizamide in order to provide a prospective, randomized, double-blind trial comparing these contrast media. The two media produced radiographs of equal quality. Contrast-related morbidity was suffered by four patients (13%) i...
full textIohexol for cervical myelography via C1-C2 puncture: study of efficacy and adverse reactions.
Cervical myelography with iohexol via C1-C2 puncture was performed in 30 patients in two medical centers using a concentration of 240 mg l/ml. The study demonstrated iohexol to be a safe contrast medium without significant changes in neurologic and physical examination, vital signs, electrocardiogram, or hematologic or blood chemistry parameters. Fifteen patients had electroencephalograms (EEGs...
full textAseptic meningoencephalitis after iohexol CT myelography.
We describe the case of a patient with aseptic meningoencephalitis after intrathecal iohexol injection for myelography and review the previous literature on similar cases of contrast-induced neurotoxicity.
full textIohexol vs. metrizamide: study of efficacy and morbidity in cervical myelography.
A double-blind study was conducted in 60 patients undergoing either cervical or more complete myelography via C1-C2 puncture. Patients received either iohexol or metrizamide at a 300 mg l/ml concentration. The contrast media were equally efficacious in the production of high-quality radiographs and CT scans. However, the incidence of adverse reactions differed markedly. Of patients receiving me...
full textMy Resources
Journal title
volume 10 issue 1
pages 23- 30
publication date 2015-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023